 Connection
Dara Aisner to Pyridines
This is a "connection" page, showing publications Dara Aisner has written about Pyridines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.444 |
|
|
|
-
Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. J Thorac Oncol. 2016 08; 11(8):1273-1281.
Score: 0.102
-
Cargnelutti M, Corso S, Pergolizzi M, M?vellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget. 2015 Mar 10; 6(7):5182-94.
Score: 0.095
-
Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar; 9(3):e21-3.
Score: 0.088
-
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1472-82.
Score: 0.076
-
Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236.
Score: 0.022
-
Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Bar?n AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer. 2013 Nov 15; 119(22):3968-75.
Score: 0.021
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.020
-
Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012 Sep 01; 18(17):4570-9.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|